Effect of rebagit on gastric mucosa in patients with nsaid gastropathy

Musaeva L. J., Akbarova D.S., Pulatova N.I., Saifieva N.H.

dc.contributor.author	Musaeva L. J., Akbarova D.S., Pulatova N.I., Saifieva N.H.
dc.date.accessioned	2022-10-07T05:41:06Z
dc.date.available	2022-10-07T05:41:06Z
dc.date.issued	2022
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/2510
dc.description.abstract	The study involved 72 patients aged 20-65 years. Patients of the first group -35 patients received antisecretory therapy: pantoprazole 40 mg x 1 time daily during 14 days. Patients of the second group -37 people, against the background of pantoprazole 40 mg x once a day for 14 days received rebagit 100 mg 3 times a day. The criteria for selection to both groups were the presence of erosive changes of gastric mucosa and fresh ulcers on endoscopic examination	en_US
dc.language.iso	en	en_US
dc.publisher	Toshkent	en_US
dc.subject	Effect of rebagit on gastric mucosa, patients with nsaid gastropathy	en_US
dc.title	Effect of rebagit on gastric mucosa in patients with nsaid gastropathy	en_US
dc.type	Thesis	en_US